| Dr Benjamin Orourke, | |
|
2030 River Rd, Eugene, OR 97404 | |
| (541) 687-7620 | |
| (541) 461-2180 |
| Full Name | Dr Benjamin Orourke |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 2030 River Rd, Eugene, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003189028 | NPI | - | NPPES |
| 0011825 | Other | OR | STATE PHARMACIST LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 0011825 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Benjamin Orourke, 2030 River Rd, Eugene, OR 97404 Ph: (541) 687-7620 | Dr Benjamin Orourke, 2030 River Rd, Eugene, OR 97404 Ph: (541) 687-7620 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
The findings of a three-year study of the National Health Service supports the Francis Report in calling for more small and compassionate leadership teams of doctors, nurses and managers to meet the huge challenges the NHS faces.
A campaign that urged GPs to 'think-twice' before putting a patient on opioid medicines is effective in reducing opioid prescribing in primary care, according to the findings of a major study.
Hearing loss is the third most common chronic illness for older adults. It can impact everyday life and can significantly affect a person's health and safety if gone untreated. Hearing aids are the most common treatment for hearing loss. However, in 2005 more than 325,000 hearing aids, less than four years old were unused according to a previous study in the Hearing Journal.
Results from a phase IIa open-label trial and a subsequent phase III open-label extension trial reinforce findings from an earlier short-term trial that adolescents with moderate-to-severe atopic dermatitis, or eczema, can experience significant improvements with dupilumab.
› Verified 9 days ago
Matthew William Kaiser, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4550 W 11th Ave, Eugene, OR 97402 Phone: 541-344-2720 | |
Everett Sutherland, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2788 River Rd, Eugene, OR 97404 Phone: 541-607-1541 | |
Nicholas Ryan Dibos, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1750 Willow Creek Cir, Eugene, OR 97402 Phone: 541-744-1641 Fax: 541-744-1052 | |
Ms. Shwu Yng Choong, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4575 W 11th Ave, T-1405, Eugene, OR 97402 Phone: 541-684-4589 Fax: 541-684-4589 | |
Scott M Davis, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2788 River Rd, Eugene, OR 97404 Phone: 541-607-1541 | |
Harold Bucholtz, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 145 E 18th Ave, Eugene, OR 97401 Phone: 541-683-9684 |